Skip to main content
. 2022 Apr 7;13:830631. doi: 10.3389/fimmu.2022.830631

Figure 1.

Figure 1

Onset time of checkpoint inhibitor pneumonitis (CIP) in NSCLC patients receiving PD-1/PD-L1 treatment. NSCLC, non-small-cell lung cancer. The curve in the figure does not represent the change in the incidence of CIP over time. The abscissa of the highest point of the curve represents the median time of CIP reported in the studies (16, 18, 34, 35, 37).